checkAd

    SciVac Therapeutics Inc.  853  0 Kommentare News Release - Seite 3

    These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the SciVac F-4 and VBI Proxy and may be set forth in other relevant materials to be filed with the SEC and with the Canadian Securities Commissions when they become available.

    Cautionary Statement on Forward-looking Information

    Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties, including statements regarding the ability of SciVac and VBI to consummate the transactions contemplated by the Proposed Merger, whereby, subject to the satisfaction of certain conditions, a wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving as a wholly owned subsidiary of SciVac.

    Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, general economic conditions and other factors detailed from time to time in the Company's periodic disclosure. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the Company's current expectations and it undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

    Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX), the Frankfurt Stock Exchange nor the OTCQX accepts responsibility for the adequacy or accuracy of this news release.

    SciVac Therapeutics Inc.
    Jim Martin
    Chief Financial Officer
    305-575-4207
    Jmartin@scivactherapeutics.com
    www.scivactherapeutics.com
    Seite 3 von 3



    Verfasst von Marketwired
    SciVac Therapeutics Inc. News Release - Seite 3 VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 2, 2016) - SciVac Therapeutics Inc. ("SciVac" or the "Company") (TSX:VAC)(OTCQX:SVACD) today announced, in connection with the previously disclosed proposed business combination between SciVac and VBI …

    Schreibe Deinen Kommentar

    Disclaimer